Lipocine (LPCN) Cash & Equivalents Growth (5y) (2016 - 2025)
Lipocine (LPCN) Cash & Equivalents Growth (5y) (2016 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.89% |
| Sep 30, 2025 | 3.09% |
| Jun 30, 2025 | 4.98% |
| Mar 31, 2025 | 5.42% |
| Dec 31, 2024 | 17.28% |
| Sep 30, 2024 | 24.36% |
| Jun 30, 2024 | 35.39% |
| Mar 31, 2024 | 24.40% |
| Dec 31, 2023 | 22.07% |
| Sep 30, 2023 | 36.82% |
| Jun 30, 2023 | 38.71% |
| Mar 31, 2023 | 27.15% |
| Dec 31, 2022 | 58.46% |
| Sep 30, 2022 | 29.47% |
| Jun 30, 2022 | 17.45% |
| Mar 31, 2022 | 42.81% |
| Dec 31, 2021 | 52.44% |
| Sep 30, 2021 | 52.03% |
| Jun 30, 2021 | 29.95% |
| Mar 31, 2021 | 2.02% |